Details of the Drug Reposition

General Information of This Drug (ID: DMKIE9C)

Drug Name
JNJ-26481585   DMKIE9C
Synonyms
875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
Advanced stage follicular lymphoma DIS8US5Q 2A80 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
2 ClinicalTrials.gov (NCT01486277) A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma